Authors: Marcy C. Zanarini, Ed.D., and Frances R. Frankenburg, M.D.
Link: http://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.160.1.167
This article described an experiment in which 30 females went through an 8-week, placebo controlled study of E-EPA for borderline personality disorder. 20 of the subjects recieved 1 g of E-EPA (while the others got placebo) and the E-EPA was superior to placebo in diminishing the agression and severity of the patients' depressive symptoms. Borderline personality disorder affects a person's mood and impulisive aggression, and most medications are only targeted towards some of the symptoms of the disorder so they do not work properly. However, omega-3 fatty acids are now recognized for their mental health benefits. EPA and DHA have important functions in the CNS because DHA is a major structural component of neuronal membranes and EPA has physiological functions that can affect neuronal activity. Biomedichal studies have shown that many patients with poor mental health had reduced levels of omega-3 fatty acids in red blood cell membranes. Overall the results of this trial suggest that EPA is a nutriceutical agent that could be beneficial to the treatment of women with borderline personality disorder. The women reported no clinically relevant side effects and these results were consistent with the findings of reports of omega-3 fatty acids as a treatment for bipolar disorder.
No comments:
Post a Comment